Loading…

Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States

•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was int...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-10, Vol.35 (45), p.6160-6165
Main Authors: Jacobs, David M., Yung, Francine, Hart, Emily, Nguyen, Melanie N.H., Shaver, Amy
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3
cites cdi_FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3
container_end_page 6165
container_issue 45
container_start_page 6160
container_title Vaccine
container_volume 35
creator Jacobs, David M.
Yung, Francine
Hart, Emily
Nguyen, Melanie N.H.
Shaver, Amy
description •Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 in the U.S. and its impact on pneumococcal meningitis (PM) is unknown. We assessed the impact of PCV13 on PM hospitalization rates 4years after the vaccine was introduced. This was a retrospective analysis of the National Inpatient Sample from 2008–2014. Patients with an ICD-9-CM code for PM (320.1) were identified and rates calculated using US Census data as the denominator. Data weights were used to derive national estimates. We examined three time periods: 2008–2009 (late post-PCV7), 2010 (transition year), and 2011–2014 (post-PCV13). During the study period, there were 10,493 hospitalizations due to PM in the U.S. Overall, PM incidence decreased from 0.62 to 0.38 cases per 100,000 over this time (39% decrease; P
doi_str_mv 10.1016/j.vaccine.2017.09.050
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1943648254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17312987</els_id><sourcerecordid>1943648254</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3</originalsourceid><addsrcrecordid>eNqFkc-O1SAYxYnRONfRR9A0ceOmFQq0sDJm4qjJJC6cSdwRCl9naFq4Ar1GH8MnHuq9muhGNiSc3_n-cBB6TnBDMOleT81BG-M8NC0mfYNlgzl-gHZE9LRuOREP0Q63HasZwV_O0JOUJowxp0Q-RmetkJxg0e3Qz-sI3qbK-WrvYV2CCcbouVrAO3_rskvVXUh7l_Xsfujsgk_VGOY5fCtyle-gOHMMdjWbVoXx1xuh9UHP4PPfRU3w03qrM1Sn2be2G3_jXQZbfc5FS0_Ro1HPCZ6d7nN0c_nu-uJDffXp_ceLt1e1oZLm2ra2pVIbzjrRat3ZTmAySiDjYGAYRDlgBOWEckYYHkYDmOmRjbKXhgpLz9GrY919DF9XSFktLhmYZ-0hrEkRyWjHRMtZQV_-g05hjb5MVyhOOt73UhaKHykTQ0oRRrWPbtHxuyJYbaGpSZ0WV1toCktVQiu-F6fq67CA_eP6nVIB3hwBKN9xcBBVMg68AesimKxscP9pcQ9cIa5O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1951657799</pqid></control><display><type>article</type><title>Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States</title><source>Elsevier</source><creator>Jacobs, David M. ; Yung, Francine ; Hart, Emily ; Nguyen, Melanie N.H. ; Shaver, Amy</creator><creatorcontrib>Jacobs, David M. ; Yung, Francine ; Hart, Emily ; Nguyen, Melanie N.H. ; Shaver, Amy</creatorcontrib><description>•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 in the U.S. and its impact on pneumococcal meningitis (PM) is unknown. We assessed the impact of PCV13 on PM hospitalization rates 4years after the vaccine was introduced. This was a retrospective analysis of the National Inpatient Sample from 2008–2014. Patients with an ICD-9-CM code for PM (320.1) were identified and rates calculated using US Census data as the denominator. Data weights were used to derive national estimates. We examined three time periods: 2008–2009 (late post-PCV7), 2010 (transition year), and 2011–2014 (post-PCV13). During the study period, there were 10,493 hospitalizations due to PM in the U.S. Overall, PM incidence decreased from 0.62 to 0.38 cases per 100,000 over this time (39% decrease; P&lt;0.01). Among children &lt;2years, the average annualized PM rate decreased by 45% from 2.19 to 1.20 per 100,000 (P=0.10). Annual PM rates decreased in those aged 18–39years (0.25–0.15 cases per 100,000; P=0.02) and 40–64years (0.95–0.54 cases per 100,000; P=0.03). A total of 1016 deaths were due to PM, and the case fatality rate was variable over the study period (8.3%–11.2%; P=0.96). Following the introduction of PCV13, hospitalization rates for PM decreased significantly with no subsequent improvements in case-fatality rate.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.09.050</identifier><identifier>PMID: 28951086</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Censuses ; Child ; Child, Preschool ; Children ; Conjugate vaccine ; Epidemiology ; Fatalities ; Female ; Hospitalization - trends ; Humans ; Immunization ; Incidence ; Inpatients - statistics &amp; numerical data ; International Classification of Diseases - statistics &amp; numerical data ; Male ; Meningitis ; Meningitis, Pneumococcal - immunology ; Meningitis, Pneumococcal - prevention &amp; control ; Middle Aged ; Mortality ; Pneumococcal Vaccines - immunology ; Retrospective Studies ; Staphylococcus aureus ; Streptococcus infections ; Streptococcus pneumoniae ; Trends ; United States ; Vaccines ; Vaccines, Conjugate - immunology ; Young Adult</subject><ispartof>Vaccine, 2017-10, Vol.35 (45), p.6160-6165</ispartof><rights>2017 Elsevier Ltd</rights><rights>Copyright © 2017 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 27, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3</citedby><cites>FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28951086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacobs, David M.</creatorcontrib><creatorcontrib>Yung, Francine</creatorcontrib><creatorcontrib>Hart, Emily</creatorcontrib><creatorcontrib>Nguyen, Melanie N.H.</creatorcontrib><creatorcontrib>Shaver, Amy</creatorcontrib><title>Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 in the U.S. and its impact on pneumococcal meningitis (PM) is unknown. We assessed the impact of PCV13 on PM hospitalization rates 4years after the vaccine was introduced. This was a retrospective analysis of the National Inpatient Sample from 2008–2014. Patients with an ICD-9-CM code for PM (320.1) were identified and rates calculated using US Census data as the denominator. Data weights were used to derive national estimates. We examined three time periods: 2008–2009 (late post-PCV7), 2010 (transition year), and 2011–2014 (post-PCV13). During the study period, there were 10,493 hospitalizations due to PM in the U.S. Overall, PM incidence decreased from 0.62 to 0.38 cases per 100,000 over this time (39% decrease; P&lt;0.01). Among children &lt;2years, the average annualized PM rate decreased by 45% from 2.19 to 1.20 per 100,000 (P=0.10). Annual PM rates decreased in those aged 18–39years (0.25–0.15 cases per 100,000; P=0.02) and 40–64years (0.95–0.54 cases per 100,000; P=0.03). A total of 1016 deaths were due to PM, and the case fatality rate was variable over the study period (8.3%–11.2%; P=0.96). Following the introduction of PCV13, hospitalization rates for PM decreased significantly with no subsequent improvements in case-fatality rate.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Censuses</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Conjugate vaccine</subject><subject>Epidemiology</subject><subject>Fatalities</subject><subject>Female</subject><subject>Hospitalization - trends</subject><subject>Humans</subject><subject>Immunization</subject><subject>Incidence</subject><subject>Inpatients - statistics &amp; numerical data</subject><subject>International Classification of Diseases - statistics &amp; numerical data</subject><subject>Male</subject><subject>Meningitis</subject><subject>Meningitis, Pneumococcal - immunology</subject><subject>Meningitis, Pneumococcal - prevention &amp; control</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Retrospective Studies</subject><subject>Staphylococcus aureus</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Trends</subject><subject>United States</subject><subject>Vaccines</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Young Adult</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkc-O1SAYxYnRONfRR9A0ceOmFQq0sDJm4qjJJC6cSdwRCl9naFq4Ar1GH8MnHuq9muhGNiSc3_n-cBB6TnBDMOleT81BG-M8NC0mfYNlgzl-gHZE9LRuOREP0Q63HasZwV_O0JOUJowxp0Q-RmetkJxg0e3Qz-sI3qbK-WrvYV2CCcbouVrAO3_rskvVXUh7l_Xsfujsgk_VGOY5fCtyle-gOHMMdjWbVoXx1xuh9UHP4PPfRU3w03qrM1Sn2be2G3_jXQZbfc5FS0_Ro1HPCZ6d7nN0c_nu-uJDffXp_ceLt1e1oZLm2ra2pVIbzjrRat3ZTmAySiDjYGAYRDlgBOWEckYYHkYDmOmRjbKXhgpLz9GrY919DF9XSFktLhmYZ-0hrEkRyWjHRMtZQV_-g05hjb5MVyhOOt73UhaKHykTQ0oRRrWPbtHxuyJYbaGpSZ0WV1toCktVQiu-F6fq67CA_eP6nVIB3hwBKN9xcBBVMg68AesimKxscP9pcQ9cIa5O</recordid><startdate>20171027</startdate><enddate>20171027</enddate><creator>Jacobs, David M.</creator><creator>Yung, Francine</creator><creator>Hart, Emily</creator><creator>Nguyen, Melanie N.H.</creator><creator>Shaver, Amy</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20171027</creationdate><title>Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States</title><author>Jacobs, David M. ; Yung, Francine ; Hart, Emily ; Nguyen, Melanie N.H. ; Shaver, Amy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Censuses</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Conjugate vaccine</topic><topic>Epidemiology</topic><topic>Fatalities</topic><topic>Female</topic><topic>Hospitalization - trends</topic><topic>Humans</topic><topic>Immunization</topic><topic>Incidence</topic><topic>Inpatients - statistics &amp; numerical data</topic><topic>International Classification of Diseases - statistics &amp; numerical data</topic><topic>Male</topic><topic>Meningitis</topic><topic>Meningitis, Pneumococcal - immunology</topic><topic>Meningitis, Pneumococcal - prevention &amp; control</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Retrospective Studies</topic><topic>Staphylococcus aureus</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Trends</topic><topic>United States</topic><topic>Vaccines</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacobs, David M.</creatorcontrib><creatorcontrib>Yung, Francine</creatorcontrib><creatorcontrib>Hart, Emily</creatorcontrib><creatorcontrib>Nguyen, Melanie N.H.</creatorcontrib><creatorcontrib>Shaver, Amy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest_Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacobs, David M.</au><au>Yung, Francine</au><au>Hart, Emily</au><au>Nguyen, Melanie N.H.</au><au>Shaver, Amy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-10-27</date><risdate>2017</risdate><volume>35</volume><issue>45</issue><spage>6160</spage><epage>6165</epage><pages>6160-6165</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 in the U.S. and its impact on pneumococcal meningitis (PM) is unknown. We assessed the impact of PCV13 on PM hospitalization rates 4years after the vaccine was introduced. This was a retrospective analysis of the National Inpatient Sample from 2008–2014. Patients with an ICD-9-CM code for PM (320.1) were identified and rates calculated using US Census data as the denominator. Data weights were used to derive national estimates. We examined three time periods: 2008–2009 (late post-PCV7), 2010 (transition year), and 2011–2014 (post-PCV13). During the study period, there were 10,493 hospitalizations due to PM in the U.S. Overall, PM incidence decreased from 0.62 to 0.38 cases per 100,000 over this time (39% decrease; P&lt;0.01). Among children &lt;2years, the average annualized PM rate decreased by 45% from 2.19 to 1.20 per 100,000 (P=0.10). Annual PM rates decreased in those aged 18–39years (0.25–0.15 cases per 100,000; P=0.02) and 40–64years (0.95–0.54 cases per 100,000; P=0.03). A total of 1016 deaths were due to PM, and the case fatality rate was variable over the study period (8.3%–11.2%; P=0.96). Following the introduction of PCV13, hospitalization rates for PM decreased significantly with no subsequent improvements in case-fatality rate.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28951086</pmid><doi>10.1016/j.vaccine.2017.09.050</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2017-10, Vol.35 (45), p.6160-6165
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_1943648254
source Elsevier
subjects Adolescent
Adult
Aged
Censuses
Child
Child, Preschool
Children
Conjugate vaccine
Epidemiology
Fatalities
Female
Hospitalization - trends
Humans
Immunization
Incidence
Inpatients - statistics & numerical data
International Classification of Diseases - statistics & numerical data
Male
Meningitis
Meningitis, Pneumococcal - immunology
Meningitis, Pneumococcal - prevention & control
Middle Aged
Mortality
Pneumococcal Vaccines - immunology
Retrospective Studies
Staphylococcus aureus
Streptococcus infections
Streptococcus pneumoniae
Trends
United States
Vaccines
Vaccines, Conjugate - immunology
Young Adult
title Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A32%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trends%20in%20pneumococcal%20meningitis%20hospitalizations%20following%20the%20introduction%20of%20the%2013-valent%20pneumococcal%20conjugate%20vaccine%20in%20the%20United%20States&rft.jtitle=Vaccine&rft.au=Jacobs,%20David%20M.&rft.date=2017-10-27&rft.volume=35&rft.issue=45&rft.spage=6160&rft.epage=6165&rft.pages=6160-6165&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.09.050&rft_dat=%3Cproquest_cross%3E1943648254%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-d2d239ac54682aa6d6801f9e1fbcebb8888ec8351354140bfce04af4f979c38d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1951657799&rft_id=info:pmid/28951086&rfr_iscdi=true